Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
Abstract Background HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC. Methods 267 HER2-positive BC wer...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-05-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02495-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849734164343947264 |
|---|---|
| author | Fangchao Zheng Feng Du Zixuan Yang Xue Wang Jian Yue Yun Ling Peng Yuan |
| author_facet | Fangchao Zheng Feng Du Zixuan Yang Xue Wang Jian Yue Yun Ling Peng Yuan |
| author_sort | Fangchao Zheng |
| collection | DOAJ |
| description | Abstract Background HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC. Methods 267 HER2-positive BC were enrolled between January 2010 and December 2011. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline characteristics. Real-world disease-free survival (DFS) and overall survival (OS) was analyzed. Results The median follow-up time was 10.3 years (interquartile range: 9.4–10.8 years). HER2/CEP17 ratio of > 7.0 was defined as the HER2 ultra-positive group; a HER2/CEP17 ratio of ≤ 7.0 was defined as the HER2 normal-positive group. After sIPTW adjustment, no differences were observed in DFS and OS when anti-HER2 therapy was unknown, and similarly in the patients who were recorded as not receive trastuzumab (all p > 0.05). Interestingly, HER2 ultra-positive group had a worse DFS than the normal-positive group (hazard ratio [HR] = 2.72, p = 0.02), but there was no difference in OS (p = 0.30) in patients did receive trastuzumab. The multivariate Cox models also showed that the HER2 ultra-positive had worse DFS than HER2 normal-positive patients (HR = 3.71; p < 0.01). Conclusion For non-metastatic HER2-positive BC with or without trastuzumab treatment, the HER2/CEP17 ratio did not predict DFS and OS. However, our study supported that HER2 ultra-positive group had a worse DFS than the normal-positive group among non-metastatic HER2-positive BC patients receiving trastuzumab; therefore, this could be a potential predictor of DFS in these patients. |
| format | Article |
| id | doaj-art-db313152b5e24fcf99a6f031c475ac85 |
| institution | DOAJ |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-db313152b5e24fcf99a6f031c475ac852025-08-20T03:07:51ZengSpringerDiscover Oncology2730-60112025-05-0116111110.1007/s12672-025-02495-2Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world studyFangchao Zheng0Feng Du1Zixuan Yang2Xue Wang3Jian Yue4Yun Ling5Peng Yuan6Department of VIP Medical Services, Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and InstituteDepartment of VIP Medical Services, Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of VIP Medical Services, Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of VIP Medical Services, Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of VIP Medical Services, Department of Medical Oncology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background HER2-positive breast cancer (BC) requires anti-HER2 therapy. We aimed to determine whether the expression of the HER2/centromeric probe for chromosome 17 (CEP17) ratio was associated with prognosis in patients with HER2-positive non-metastatic BC. Methods 267 HER2-positive BC were enrolled between January 2010 and December 2011. Stabilized inverse probability treatment weighting (sIPTW) was used to balance baseline characteristics. Real-world disease-free survival (DFS) and overall survival (OS) was analyzed. Results The median follow-up time was 10.3 years (interquartile range: 9.4–10.8 years). HER2/CEP17 ratio of > 7.0 was defined as the HER2 ultra-positive group; a HER2/CEP17 ratio of ≤ 7.0 was defined as the HER2 normal-positive group. After sIPTW adjustment, no differences were observed in DFS and OS when anti-HER2 therapy was unknown, and similarly in the patients who were recorded as not receive trastuzumab (all p > 0.05). Interestingly, HER2 ultra-positive group had a worse DFS than the normal-positive group (hazard ratio [HR] = 2.72, p = 0.02), but there was no difference in OS (p = 0.30) in patients did receive trastuzumab. The multivariate Cox models also showed that the HER2 ultra-positive had worse DFS than HER2 normal-positive patients (HR = 3.71; p < 0.01). Conclusion For non-metastatic HER2-positive BC with or without trastuzumab treatment, the HER2/CEP17 ratio did not predict DFS and OS. However, our study supported that HER2 ultra-positive group had a worse DFS than the normal-positive group among non-metastatic HER2-positive BC patients receiving trastuzumab; therefore, this could be a potential predictor of DFS in these patients.https://doi.org/10.1007/s12672-025-02495-2Breast cancerHER2HER2/CEP17 ratioPrognosisTrastuzumab |
| spellingShingle | Fangchao Zheng Feng Du Zixuan Yang Xue Wang Jian Yue Yun Ling Peng Yuan Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study Discover Oncology Breast cancer HER2 HER2/CEP17 ratio Prognosis Trastuzumab |
| title | Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study |
| title_full | Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study |
| title_fullStr | Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study |
| title_full_unstemmed | Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study |
| title_short | Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study |
| title_sort | potential prognostic value of her2 cep17 fish ratio in her2 positive non metastatic breast cancer a real world study |
| topic | Breast cancer HER2 HER2/CEP17 ratio Prognosis Trastuzumab |
| url | https://doi.org/10.1007/s12672-025-02495-2 |
| work_keys_str_mv | AT fangchaozheng potentialprognosticvalueofher2cep17fishratioinher2positivenonmetastaticbreastcancerarealworldstudy AT fengdu potentialprognosticvalueofher2cep17fishratioinher2positivenonmetastaticbreastcancerarealworldstudy AT zixuanyang potentialprognosticvalueofher2cep17fishratioinher2positivenonmetastaticbreastcancerarealworldstudy AT xuewang potentialprognosticvalueofher2cep17fishratioinher2positivenonmetastaticbreastcancerarealworldstudy AT jianyue potentialprognosticvalueofher2cep17fishratioinher2positivenonmetastaticbreastcancerarealworldstudy AT yunling potentialprognosticvalueofher2cep17fishratioinher2positivenonmetastaticbreastcancerarealworldstudy AT pengyuan potentialprognosticvalueofher2cep17fishratioinher2positivenonmetastaticbreastcancerarealworldstudy |